Mymetics Corp (MYMX)

[Work Harder]

Oncology:

Mymetics has strong data that shows that its virosomes have the capability to not only trigger good antibody responses, but also are able to trigger specific T-Cell responses as virosomes are able to be absorbed and processed by dendritic cells when specific antigens are incorporated into virosomes. This is of particular importance for developing a specific cancer immunotherapy.

However, othere projects are still ongoing. One of these projects started in May 2020, which is a research project with IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology. Due to Covid-19 restrictions, the study was delayed, but the collaboration is still in place.

I left out Etherna LOL

10K

https://www.otcmarkets.com/filing/html?id=14842380&guid=OPenUp38d5ci33h

The Company’s partner for the oncology immunotherapy project in the Netherlands has decreased their laboratory experiments due to reduced operating hours in those facilities. While the Company considers this disruption to be temporary, continued disruption in this project will lead to delayed advances by the Company of its research and could negatively impact revenue for the remainder of fiscal year 2021 and the Company’s overall liquidity.

10Q

https://www.otcmarkets.com/filing/html?id=14965300&guid=OPenUp38d5ci33h

T-win® technology Merck

https://www.iobiotech.com/index.php/news/77-io102-012-futility

IO Biotech raises $155M to trial IDO and PD-L1 cancer

RA Capital Management

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine
delivery technology in combination with IO Biotech’s T-win® technology.

https://backend.otcmarkets.com/otcapi/company/dns/news/document/41834/content

Have a good week everyone